CoChat

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis

Open access
Yoshino, Takayuki, Taieb, Julien, Kuboki, Yasutoshi, Pfeiffer, Per, Kumar, Amit, Hochster, Howard S. · 2023 · Therapeutic Advances in Medical Oncology

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Background: Trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) has shown efficacy and tolerability in refractory metastatic colorectal cancer (mCRC). Because randomized controlled trial (RCT) data comparing FTD/TPI + BEV with FTD/TPI are lacking, this meta-analysis evaluated outcomes with both regimens. Data Sources and Methods: Electronic databases, congress proceedings (past 3 years), trial registries, systematic review bibliographies, gray literature, and guidelines through June 2021 were searched for RCTs, non-RCTs, and prospective observational studies involving >20 previously treated patients with mCRC receiving FTD/TPI + BEV or FTD/TPI. Absolute and relative disease control rate (DCR), progression-free survival (PFS), overall survival (OS), adverse event (AE) rates, and discontinuation rates due to AEs were evaluated using fixed-effects and random-effects models. Study quality, heterogeneity, and publication bias were assessed. Results: In all, 29 of 875 screened publications were selected (26 studies: 5 RCTs, 11 non-RCTs, and 10 prospective observational studies). One RCT compared FTD/TPI + BEV with FTD/TPI. FTD/TPI + BEV versus FTD/TPI had a higher absolute DCR [64% (6 studies; n = 289) versus 43% (10 studies; n = 2809)], median PFS [4.2 (5 studies; n = 244) versus 2.6 (6 studies; n = 1781) months], 12-month PFS [9% (5 studies; n = 244) versus 3% (6 studies; n = 1781)], median OS [9.8 (5 studies; n = 244) versus 8.1 (6 studies; n = 1814) months], and 12-month OS [38% (5 studies; n = 244) versus 32% (6 studies; n = 1814)]. Grade ⩾3 febrile neutropenia, asthenia/fatigue, diarrhea, nausea, and vomiting rates were similar (1%–7%). Grade ⩾3 neutropenia rate was higher with FTD/TPI + BEV than with FTD/TPI [43% (6 studies; n = 294) versus 29% (12 studies; n = 7139)]. Discontinuation rates due to AEs were similar [8% (5 studies; n = 244) and 7% (10 studies; n = 3724)]. Low study quality, heterogeneity, and/or publication bias were detected in certain instances. Conclusion: Despite fewer patients treated with the combination, this meta-analysis consistently suggested that FTD/TPI + BEV provides benefits over FTD/TPI in refractory mCRC and has similar safety, except for more frequent grade ⩾3 neutropenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/17588359221146137

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. PRISMA diagram. Only records for RCTs, non-RCTs, and prospective observational studies with a sample size of more than 20 patients were included in the quantitative synthesis. RCTs, randomized controlled trials; TiAb, title and abstract.
Figure 1. PRISMA diagram. Only records for RCTs, non-RCTs, and prospective observational studies with a sample size of more than 20 patients were included in the quantitative synthesis. RCTs, randomized controlled trials; TiAb, title and abstract.CC BY-NC · PubMed Central
Figure 2. Absolute (pooled) DCRs for (a) FTD/TPI + BEV and (b) FTD/TPI monotherapy. CI, confidence interval; DCRs, disease control rates; FE, fixed effects; FTD/TPI, trifluridine/tipiracil; FTD/TPI + BEV, trifluridine/tipiracil + bevacizumab; RE, random effects.
Figure 2. Absolute (pooled) DCRs for (a) FTD/TPI + BEV and (b) FTD/TPI monotherapy. CI, confidence interval; DCRs, disease control rates; FE, fixed effects; FTD/TPI, trifluridine/tipiracil; FTD/TPI + BEV, trifluridine/tipiracil + bevacizumab; RE, random effects.CC BY-NC · PubMed Central
Figure 3. Pooled absolute (a) PFS and (b) OS for FTD/TPI + BEV and FTD/TPI monotherapy. FTD/TPI, trifluridine/tipiracil; FTD/TPI + BEV, trifluridine/tipiracil + bevacizumab; NA, not applicable; OS, overall survival; PFS, progression-free survival.
Figure 3. Pooled absolute (a) PFS and (b) OS for FTD/TPI + BEV and FTD/TPI monotherapy. FTD/TPI, trifluridine/tipiracil; FTD/TPI + BEV, trifluridine/tipiracil + bevacizumab; NA, not applicable; OS, overall survival; PFS, progression-free survival.CC BY-NC · PubMed Central
Figure 4. Absolute (pooled) rates for grade ⩾3 AEs for FTD/TPI + BEV and FTD/TPI monotherapy. (a) FTD/TPI + BEV: Grade ⩾3 neutropenia. (b) FTD/TPI monotherapy: Grade ⩾3 neutropenia. (c) FTD/TPI + BEV: Grade ⩾3 febrile neutropenia. (d) FTD/TPl monotherapy: Grade ⩾3 febrile neutropenia. (e) FTD/TPI + BEV: Grade ⩾3 asthenia/fatigue. (f). FTD/TPI monotherapy: Grade ⩾3 asthenia/fatigue. (g) FTD/TPI + BEV: Grade ⩾3 diarrhea. (h) FTD/TPI monotherapy: Grade ⩾3 diarrhea. (i) FTD/TPI + BEV: Grade ⩾3 nausea. (j) FTD/TPI monotherapy: Grade ⩾3 nausea. (k) FTD/TPI + BEV: Grade ⩾3 vomiting. (l) FTD/TPI monotherapy: Grade ⩾3 vomiting. AEs, adverse events; CI, confidence interval; FE, fixed effects; FTD/TPI, trifluridine/tipiracil; FTD/TPI + BEV, trifluridine/tipiracil + bevacizumab; RE, random effects.
Figure 4. Absolute (pooled) rates for grade ⩾3 AEs for FTD/TPI + BEV and FTD/TPI monotherapy. (a) FTD/TPI + BEV: Grade ⩾3 neutropenia. (b) FTD/TPI monotherapy: Grade ⩾3 neutropenia. (c) FTD/TPI + BEV: Grade ⩾3 febrile neutropenia. (d) FTD/TPl monotherapy: Grade ⩾3 febrile neutropenia. (e) FTD/TPI + BEV: Grade ⩾3 asthenia/fatigue. (f). FTD/TPI monotherapy: Grade ⩾3 asthenia/fatigue. (g) FTD/TPI + BEV: Grade ⩾3 diarrhea. (h) FTD/TPI monotherapy: Grade ⩾3 diarrhea. (i) FTD/TPI + BEV: Grade ⩾3 nausea. (j) FTD/TPI monotherapy: Grade ⩾3 nausea. (k) FTD/TPI + BEV: Grade ⩾3 vomiting. (l) FTD/TPI monotherapy: Grade ⩾3 vomiting. AEs, adverse events; CI, confidence interval; FE, fixed effects; FTD/TPI, trifluridine/tipiracil; FTD/TPI + BEV, trifluridine/tipiracil + bevacizumab; RE, random effects.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 3

  1. Tsukihara H, 2015, Oncol Rep, 33, 2135
  2. Karthaus M, 2016, Oncol Res Treat, 39, 1
  3. Drug combination meets survival endpoint in phase III pivotal trial involving participants with refractory metastatic colorectal cancer [press release] . Paris, France: Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd. 2022.

Cited by

See all 12

Metadata

Authors
Yoshino, T., Taieb, J., Kuboki, Y., Pfeiffer, P., Kumar, A., & Hochster, H. S.
Affiliations
  • National Cancer Center Hospital East (JP)
  • Hôpital Européen Georges-Pompidou, Université Paris-Cité, SIRIC CARPEM, Paris, France
  • Odense University Hospital (DK)
  • SmartAnalyst India Pvt Ltd, Gurugram, Haryana, India
  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
Corresponding author
Yoshino, Takayuki
Venue
Therapeutic Advances in Medical Oncology
Published
2023-01
Volume
15
Pages
17588359221146137-17588359221146137
ISSN
  • 1758-8340 (ISSN-L)
  • 1758-8359
OpenAlex
W4317653767
Cited by
12
References
51
Citations by year
2025: 4 · 2024: 5 · 2023: 3
FWCI
0.39
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Medical Oncology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Taiho Oncology, Inc.
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords
trifluridine/tipiracil, bevacizumab, metastatic colorectal cancer, refractory colorectal cancer, disease control rate, progression-free survival, overall survival, adverse events, febrile neutropenia, neutropenia, treatment discontinuation, combination chemotherapy, anti-VEGF therapy, drug safety and tolerability, quality of evidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1177/17588359221146137
The paper
Yoshino, T., Taieb, J., Kuboki, Y., Pfeiffer, P., Kumar, A., & Hochster, H. S. (2023). Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/17588359221146137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.